Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Docetaxel/Cisplatin Chemoradiation in Resectable IIIA-N2 NSCLC
NCT01771289Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2013
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, cisplatin in non-small cell lung cancer (NSCLC), sponsored by Peking University People's Hospital. Status: unknown.
02
Drugs
docetaxelcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01771289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01771289.